Impact of BRAF, TERT, and novel mutations on the efficacy of lenvatinib for advanced papillary thyroid cancer: A national genomic database analysis.

NPJ Precis Oncol · 2026 · PMC13149585 · PMID 41851192

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

borderline significantp = 0.07so close (0.05 < p ≤ 0.1)

BRAF mutation versus wildtype demonstrated a borderline significant protective effect with an adjusted HR of 0.62 (95% CI: 0.37–1.04, p = 0.07).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.